Pipeline
We are building a robust pipeline of transformative medicines addressing inflammatory and autoimmune diseases, and fibrosis.
Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:
Immunology
Program
Target ID & Validation
Lead Optimization
IND Enabling
Phase 1
TRB-051*
IND Enabling
TRB-061
Lead Optimization
TRB-031*
Lead Optimization
TRB-041*
Lead Optimization
TRB-071
Target ID & Validation
TRB-081
Target ID & Validation
*In collaboration with Eli Lilly
Immunology
Oncology
*Partnered with Eli Lilly.
Discovery Pipeline
In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.
Our Collaborations
We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 3 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, and TRB-051. We also entered into a collaboration with Johnson & Johnson Innovative Medicine for novel targets in Immunology & Inflammation.
